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ABSTRACT: The rate of smoking in patients with schizophrenia is higher than that in 
the general population. Nicotinic acetylcholine receptors (nAChR) are involved in the 
sensorimotor gating defi cits in schizophrenia. We have revealed that nicotine ameliorates the 
disruption of the PPI, a model of sensorimotor gating, which is induced by apomorphine, 
a dopamine receptor agonist, in rats. Furthermore, the ameliorating effect of nicotine is 
antagonized by methyllylcaconitine, a selective α7 nAChR antagonist. The effect of nicotine 
was also investigated in the stereotyped behavior induced by apomorphine, however, nicotine 
was found to have no signifi cant effect. Considering these results, the ameliorating effect of 
the disruption of the PPI via α7 nAChR is therefore thought to be involved in dopaminergic 
systems. The dopaminergic systems involved in α7 nAChR may be different from the systems 








そこで、PPI 障害モデルにおける nicotine の障害改善作用、PPI 障害モデルにおける
tropisetron の障害改善作用等を検討したところ、tropisetron が制吐薬としてだけでなく、
統合失調症に伴う認知障害・情報処理障害改善薬となりうる可能性が示された。また、
nicotine acetylcholine receptors フルアゴニスト活性を有する新規抗精神病薬の開発が期
待される。
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